> top > docs > PubMed:22534864 > annotations

PubMed:22534864 JSONTXT

Annnotations TAB JSON ListView MergeView

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 218-224 HP_0002018 denotes nausea
T2 229-237 HP_0002013 denotes vomiting
T3 279-285 HP_0002018 denotes nausea

Allie

Id Subject Object Predicate Lexical cue
SS1_22534864_2_0 197-237 expanded denotes chemotherapy-induced nausea and vomiting
SS2_22534864_2_0 239-243 abbr denotes CINV
SS1_22534864_3_0 493-504 expanded denotes food intake
SS2_22534864_3_0 506-508 abbr denotes FI
SS1_22534864_3_1 550-581 expanded denotes multiple day-based chemotherapy
SS2_22534864_3_1 583-588 abbr denotes MD-CT
SS1_22534864_8_0 937-954 expanded denotes Complete response
SS2_22534864_8_0 956-958 abbr denotes CR
SS1_22534864_8_1 1027-1043 expanded denotes complete control
SS2_22534864_8_1 1045-1047 abbr denotes CC
AE1_22534864_2_0 SS1_22534864_2_0 SS2_22534864_2_0 abbreviatedTo chemotherapy-induced nausea and vomiting,CINV
AE1_22534864_3_0 SS1_22534864_3_0 SS2_22534864_3_0 abbreviatedTo food intake,FI
AE1_22534864_3_1 SS1_22534864_3_1 SS2_22534864_3_1 abbreviatedTo multiple day-based chemotherapy,MD-CT
AE1_22534864_8_0 SS1_22534864_8_0 SS2_22534864_8_0 abbreviatedTo Complete response,CR
AE1_22534864_8_1 SS1_22534864_8_1 SS2_22534864_8_1 abbreviatedTo complete control,CC

PubMed_Structured_Abstracts

Id Subject Object Predicate Lexical cue
T1 154-590 BACKGROUND denotes The goal of pharmacological prophylaxis of chemotherapy-induced nausea and vomiting (CINV) should be the elimination of both nausea and vomiting symptoms during all planned chemotherapy cycles. The aim of this study was to assess the efficacy of a single dose of palonosetron and dexamethasone to prevent CINV and to guarantee an adequate food intake (FI) in patients receiving several cycles of multiple day-based chemotherapy (MD-CT).
T2 600-1229 METHODS denotes Patients with advanced cancer but without a compromised nutritional status (bone mass index ≥ 18.5) were treated with 0.25 mg palonosetron plus 20 mg dexamethasone before MD-CT. The MD-CT regimen was either epirubicin plus ifosfamide or paclitaxel plus cisplatin and ifosfamide. Nausea, vomiting, and FI were monitored in a 7-day diary. Complete response (CR: no vomiting and no rescue therapy) was the primary endpoint, while complete control (CC: CR and no more than mild nausea) and the evaluation of FI were secondary endpoints. The endpoints were evaluated during the overall timescale (0-168 h) of the chemotherapy regimen.
T3 1239-1544 RESULTS denotes Fifty patients were enrolled, 80% of whom achieved CR and 78% achieved CC. During the six chemotherapy cycles, CR and CC ranged from 76% to 88% and from 62% to 88%, respectively. Moreover, patients with CR had a significantly (p < 0.0001) higher weekly food intake compared with patients not achieving CR.
T4 1558-2111 CONCLUSIONS denotes This trial was the first to assess the efficacy of palonosetron and dexamethasone for the prevention of both nausea and vomiting in patients receiving multiple cycles of MD-CT. In this trial, the ability of patients to intake an adequate amount of food each week was correlated with nausea, thus providing clinicians with an objective parameter for the measurement of the effects of nausea. A single dose of palonosetron and dexamethasone was able to prevent CINV in most patients receiving 3 days of chemotherapy during all planned chemotherapy cycles.